Document is current

Article History

Received: 7 April 2025

Accepted: 1 June 2025

First Online: 20 June 2025

Declarations

:

: Petra Stute received honoraria for speaking engagements from Besins Healthcare, Exeltis, Jenapharm, Bayer, Drossapharm, Theramex, Gedeon-Richter, Viatris, Astellas, Effik, Hexal, Labatec, Pierre Fabre, Pharmacosmos, Vifor, Zeller, and Schaer Pharma, and served as a consultant for Theramex, Astellas, Pharmacosmos, and Bionorica. Pierre-Alexandre Krayenbühl received consulting fees from Pierre Fabre and Vifor Pharma. Stephan R. Vavricka has received consulting fees, speaker honoraria, and unrestricted research grants from Abbott, Alfasigma, Amgen, Arenapharm, BMS, Falk Pharma GmbH, Ferring Pharmaceuticals, Gilead, iQuone, Janssen, MSD, Permamed, Pfizer Inc., Pharmacosmos, Pierre Fabre, Sanofi-Aventis, Schwabe Pharma, Takeda, Tillotts, UCB, and Vifor.

: The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice as prescribed by Swissmedic and the European Medicines Agency criteria for non-interventional studies, and approved by the Kantonale Ethikkommission Zurich (BASEC-No. 2020–00119, 26 March 2020). The study was registered on ClinicalTrials.gov (NCT04318405). The data were anonymized upon completion of the analyses, except for pharmacovigilance data, which were processed on a pseudonymous basis due to legal requirements.

: All participants provided written informed consent before inclusion in the study.